Rafferty Asset Management’s Iovance Biotherapeutics IOVA Stock Holding History

Rafferty Asset Management’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.68M	Sell	402,880 -30,119	-7%	-$114K	﹤0.01%	680
2026 Q1	$1.52M	Sell	432,999 -273,451	-39%	-$875K	0.01%	666
2025 Q4	$1.93M	Buy	706,450 +223,475	+46%	+$517K	0.01%	653
2025 Q3	$1.05M	Buy	482,975 +190,522	+65%	+$450K	﹤0.01%	786
2025 Q2	$503K	Sell	292,453 -129,076	-31%	-$321K	﹤0.01%	885
2025 Q1	$1.4M	Sell	421,529 -132,612	-24%	-$684K	0.01%	669
2024 Q4	$4.1M	Sell	554,141 -98,825	-15%	-$916K	0.01%	454
2024 Q3	$6.13M	Sell	652,966 -71,213	-10%	-$675K	0.02%	371
2024 Q2	$5.81M	Buy	724,179 +140,068	+24%	+$1.5M	0.02%	390
2024 Q1	$8.66M	Sell	584,111 -663,404	-53%	-$7.72M	0.03%	321
2023 Q4	$10.1M	Sell	1,247,515 -248,655	-17%	-$1.3M	0.04%	274
2023 Q3	$6.81M	Buy	1,496,170 +443,249	+42%	+$2.89M	0.04%	330
2023 Q2	$7.41M	Sell	1,052,921 -42,518	-4%	-$304K	0.04%	315
2023 Q1	$6.69M	Sell	1,095,439 -70,259	-6%	-$485K	0.05%	308
2022 Q4	$7.45M	Buy	1,165,698 +547,013	+88%	+$4.27M	0.06%	283
2022 Q3	$5.93M	Buy	618,685 +158,605	+34%	+$1.83M	0.06%	296
2022 Q2	$5.08M	Buy	460,080 +54,372	+13%	+$713K	0.05%	273
2022 Q1	$6.75M	Buy	405,708 +120,202	+42%	+$1.86M	0.04%	283
2021 Q4	$5.45M	Buy	285,506 +148,649	+109%	+$3.27M	0.03%	356
2021 Q3	$3.38M	Buy	136,857 +25,622	+23%	+$604K	0.02%	415
2021 Q2	$2.89M	Buy	111,235 +15,186	+16%	+$395K	0.02%	510
2021 Q1	$3.04M	Buy	96,049 +77,386	+415%	+$3.21M	0.02%	485
2020 Q4	$866K	Sell	18,663 -43,929	-70%	-$1.74M	0.01%	542
2020 Q3	$2.06M	Buy	62,592 +30,227	+93%	+$927K	0.02%	408
2020 Q2	$888K	Buy	32,365 +20,237	+167%	+$665K	0.01%	581
2020 Q1	$363K	Sell	12,128 -90,862	-88%	-$2.41M	0.02%	388
2019 Q4	$2.85M	Sell	102,990 -138,670	-57%	-$3.15M	0.04%	233
2019 Q3	$4.4M	Buy	241,660 +145,274	+151%	+$3.21M	0.07%	169
2019 Q2	$2.36M	Sell	96,386 -52,051	-35%	-$784K	0.04%	327
2019 Q1	$1.41M	Buy	+148,437	New	+$1.44M	0.02%	481

Other funds holding IOVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

MFM

MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Rafferty Asset Management's IOVA Position: Q2 2026 in Review

Rafferty Asset Management reduced its Iovance Biotherapeutics (IOVA) stake by 7% in Q2 2026, selling an estimated $114K and leaving 402,880 shares worth $1.68M. The position accounts for ﹤0.01% of the portfolio, ranked #680.

Rafferty Asset Management first reported a position in IOVA in Q1 2019 and has held it in 30 quarters since. The position peaked at $10.1M in Q4 2023. 292 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

Rafferty Asset Management held 402,880 shares of Iovance Biotherapeutics worth $1.68M as of Q2 2026.
Rafferty Asset Management sold 30,119 Iovance Biotherapeutics shares in Q2 2026, an estimated $114K.
Iovance Biotherapeutics made up ﹤0.01% of Rafferty Asset Management's portfolio in Q2 2026, its #680 holding.
Rafferty Asset Management first reported a position in Iovance Biotherapeutics in Q1 2019 and has held it in 30 quarters since.
Rafferty Asset Management's Iovance Biotherapeutics position peaked at $10.1M in Q4 2023.
292 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on Rafferty Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.